C4 Therapeutics, Inc
CCCC
NASDAQ
Biotechnology
$4.24
USD
+0.16 (+3.92%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $497.64M
Volume 3.4M
Revenue
$35.04M
TTM
+2.3%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$-101.42M
TTM
+9.1%
YoY
Operating Cash Flow
$-84.87M
TTM
+2.9%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 6.5 | 11.2 | 11.0 | 6.2 | 6.6 |
YoY Growth | -46.2% | -26.9% | +112.8% | -15.0% | +2.8% |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 6.5 | 11.2 | 11.0 | 6.2 | 6.6 |
Selling, General & Administrative | 8.8 | 8.9 | 9.2 | 9.3 | 8.6 |
Other Operating Expenses | 0.0 | 10.7 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 35.0 | 45.6 | 34.2 | 33.9 | 33.1 |
Operating Income | -28.5 | -34.4 | -23.1 | -27.8 | -26.4 |
EBITDA | -27.9 | -23.2 | -22.7 | -27.4 | -26.1 |
Other Income / Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Other Income / Expense | 2.5 | 2.2 | 2.8 | 2.7 | 2.8 |
Income Before Income Taxes | -26.0 | -32.2 | -20.4 | -25.1 | -23.6 |
Income Taxes | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 |
Net Income | -26.0 | -32.2 | -20.5 | -25.1 | -23.6 |
Consolidated Net Income / Loss | -26.0 | -32.2 | -20.5 | -25.1 | -23.6 |
Net Income Attributable to Common Shareholders | -26.0 | -32.2 | -20.5 | -25.1 | -23.6 |
Basic EPS | -$0.37 | -$0.44 | -$0.17 | -$0.20 | -$0.18 |
Diluted EPS | -$0.37 | -$0.44 | -$0.17 | -$0.20 | -$0.18 |
Basic Shares Outstanding | 71.0M | 72.6M | 117.2M | 126.1M | 130.7M |
Diluted Shares Outstanding | 71.0M | 72.6M | 117.2M | 126.1M | 130.7M |